Active Ingredient History
Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive CML. Imatinib (GLEEVEC®) inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. It is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib (GLEEVEC®) inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypereosinophilic Syndrome (approved 2001)
Mastocytosis, Systemic (approved 2001)
Myelodysplastic-Myeloproliferative Diseases (approved 2001)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (approved 2001)
Abdominal Neoplasms (Phase 2)
Acute Lung Injury (Phase 1)
Adenocarcinoma of Lung (Phase 2)
Alveolitis, Extrinsic Allergic (Phase 1/Phase 2)
Anemia (Phase 1)
Anemia, Sickle Cell (Early Phase 1)
Antineoplastic Agents (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Asthma (Phase 2)
Astrocytoma (Phase 3)
Bile Duct Neoplasms (Phase 2)
Biomarkers (Phase 2)
Blast Crisis (Phase 2)
Bone Marrow Diseases (Phase 3)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 4)
Breast Neoplasms, Male (Phase 2)
Burkitt Lymphoma (Phase 1)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 1/Phase 2)
Chondrosarcoma (Phase 2)
Chordoma (Phase 2)
Choroidal Neovascularization (Phase 1)
Chronic Disease (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Coronavirus Infections (Phase 3)
COVID-19 (Phase 3)
Dermatofibrosarcoma (Phase 2)
Diabetes Mellitus, Type 1 (Phase 2)
Drug Misuse (Phase 1/Phase 2)
Drugs, Investigational (Phase 2/Phase 3)
Dyskinesia, Drug-Induced (Phase 2)
Edema (Phase 2)
Endometrial Neoplasms (Phase 1/Phase 2)
Endothelial Cells (Phase 2)
Eosinophilia (Phase 2)
Eosinophils (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fibroma (Phase 2)
Fibromatosis, Aggressive (Phase 2)
Fibrosarcoma (Phase 2)
Gastrointestinal Stromal Tumors (Phase 4)
Genital Diseases, Male (Phase 2)
Genital Neoplasms, Male (Phase 2)
Glioblastoma (Phase 3)
Glioma (Phase 1/Phase 2)
Gliosarcoma (Phase 2)
Graft vs Host Disease (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Health (Phase 2)
Healthy Volunteers (Phase 1/Phase 2)
Hematologic Diseases (Phase 3)
Hematologic Neoplasms (Phase 4)
Hematopoietic Stem Cells (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2/Phase 3)
Hodgkin Disease (Phase 1)
Hypereosinophilic Syndrome (Phase 2)
Hypertension, Pulmonary (Phase 3)
Idiopathic Pulmonary Fibrosis (Phase 2/Phase 3)
Imatinib Mesylate (Phase 2)
Immunoglobulin Light-chain Amyloidosis (Phase 1)
Intestinal Neoplasms (Phase 4)
Intraocular Lymphoma (Phase 1)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 4)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 1)
Leukemia, Large Granular Lymphocytic (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 3)
Leukemia-Lymphoma, Adult T-Cell (Phase 1/Phase 2)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Accelerated Phase (Phase 2)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myeloid, Chronic-Phase (Phase 3)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Neutrophilic, Chronic (Phase 1)
Leukemia, Prolymphocytic (Phase 1)
Lung Diseases (Phase 2/Phase 3)
Lung Neoplasms (Phase 2)
Lymphangioleiomyomatosis (Phase 1/Phase 2)
Lymphoma (Phase 2)
Lymphoma, AIDS-Related (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 1)
Macular Edema (Phase 2)
Malaria, Falciparum (Phase 2)
Mastocytosis, Systemic (Phase 4)
Maximum Tolerated Dose (Phase 1/Phase 2)
Melanoma (Phase 2)
Meninges (Phase 2)
Meningioma (Phase 2)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Mucositis (Phase 3)
Multiple Myeloma (Phase 1)
Multiple Sclerosis (Phase 2)
Mutation (Phase 3)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasm, Residual (Phase 2/Phase 3)
Neoplasms ()
Neoplasms, Squamous Cell (Phase 2)
Nephrogenic Fibrosing Dermopathy (Phase 3)
Neuroblastoma (Phase 2)
Neuroendocrine Tumors (Phase 2)
Neurofibroma (Phase 1/Phase 2)
Neurofibroma, Plexiform (Phase 2)
Neurofibromatoses (Phase 2)
Neurofibrosarcoma (Phase 2/Phase 3)
Oligodendroglioma (Phase 1/Phase 2)
Osteosarcoma (Phase 2)
Ovarian Diseases (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Parasitemia (Phase 2)
Parkinson Disease (Phase 2)
Philadelphia Chromosome (Phase 3)
Plasmacytoma (Phase 1)
Pleural Effusion, Malignant (Phase 2)
Polycythemia Vera (Phase 2)
Postmenopause (Phase 2)
Primary Myelofibrosis (Phase 2)
Progression-Free Survival (Phase 2)
Prostatic Diseases (Phase 2)
Prostatic Neoplasms (Phase 2)
Proto-Oncogene Proteins c-kit (Phase 2)
Pulmonary Arterial Hypertension (Phase 3)
Pulmonary Edema (Phase 2)
Pulmonary Fibrosis (Phase 2/Phase 3)
Pulmonary Veno-Occlusive Disease (Phase 1/Phase 2)
Quality of Health Care (Phase 2)
Respiratory Distress Syndrome (Phase 2)
Respiratory Tract Diseases (Phase 2)
Rhinitis, Allergic, Seasonal (Phase 1/Phase 2)
Sarcoma (Phase 3)
Sarcoma, Ewing (Phase 2)
Sarcoma, Synovial (Phase 2)
SARS Virus (Phase 2)
Scleroderma, Localized (Phase 2)
Scleroderma, Systemic (Phase 2)
Severe Acute Respiratory Syndrome (Phase 2)
Sezary Syndrome (Phase 1)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Spinal Cord Injuries (Phase 2)
Stem Cell Transplantation (Phase 2)
Stomach Neoplasms (Phase 2)
Stroke (Phase 3)
Substance Withdrawal Syndrome (Phase 2)
Testicular Neoplasms (Phase 2)
Therapeutics (Phase 2)
Thoracic Neoplasms (Phase 2)
Thrombocythemia, Essential (Phase 2)
Thymoma (Phase 1)
Thyroid Cancer, Papillary (Phase 1)
Thyroid Neoplasms (Phase 2)
Tuberculosis (Phase 2)
Urogenital Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
